InsidersTradesSigma
Track the Imprimis Pharmaceuticals, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 3 February 2016 (Levée d'options). Among the most active insiders: BOLL ANDREW R.. Every trade is accessible without an account.
Analysts rate Imprimis Pharmaceuticals, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Imprimis Pharmaceuticals, Inc. 是一家专注于定制药物开发的公司。它致力于提供创新的药物解决方案以满足患者需求。